On April 24, 2026, the FDA issued Commissioner’s National Priority Vouchers (CNPVs) to three companies developing psychedelic therapies for depression and PTSD. The move could shorten review timelines from roughly a year to one or two months, according to NBC News. FDA Commissioner Marty Makary told NBC News the agency could potentially approve the first psychedelic drug “by the end of summer.”
If you or someone you care about is living with treatment-resistant depression, PTSD, or another serious mental health condition, this news raises practical questions. What drugs are being reviewed? When might they become available? And what does it mean for treatments like ketamine therapy that are already accessible today?
Here is what we know so far, what remains uncertain, and how to think about your options right now.
What the FDA actually did
The FDA awarded three CNPVs through its priority voucher program, which launched in June 2025. The program accelerates review of drugs the agency considers nationally important. A voucher does not guarantee approval. It means the FDA will aim to complete its review in one to two months instead of the typical 10 to 12, with more frequent communication between the agency and each drugmaker.
The vouchers followed an executive order signed by President Trump on April 18, 2026, directing federal agencies to speed access to psychedelic therapies for serious mental illness. The order instructed the FDA to issue priority vouchers to psychedelic drugs that hold Breakthrough Therapy designation.
While the FDA did not name the recipients, reporting from Fierce Biotech, BioSpace, and other outlets identified the three companies and their therapies:
- Compass Pathways received a voucher for COMP360, a synthetic psilocybin (the active compound in psychedelic mushrooms) being studied for treatment-resistant depression (TRD). Compass confirmed its voucher publicly and announced the FDA also approved its rolling new drug application. In a phase 3 trial with over 1,000 participants, Compass reported that people with TRD experienced effects within a day, with clinically meaningful responses lasting at least six months.
- Usona Institute, a nonprofit research organization, received a voucher for PSIL201, another psilocybin-based therapy focused on major depressive disorder (MDD). Usona’s program earned Breakthrough Therapy designation from the FDA in 2019 and is currently in phase 3 trials.
- Transcend Therapeutics (being acquired by Otsuka Pharmaceutical for up to $1.225 billion) received a voucher for TSND-201, a methylone-based drug for PTSD. Methylone is related to MDMA but does not produce hallucinogenic effects through the 5-HT2A receptor. A phase 2 study published in JAMA Psychiatry found significant PTSD symptom improvement at 64 weeks after four weekly oral doses.
All three hold Breakthrough Therapy designation, which the FDA grants when early clinical evidence suggests a drug may offer meaningful improvement over existing treatments.
What “fast-tracked” actually means (and what it doesn’t)
Speed sounds encouraging, but the details matter.
The priority voucher shortens the FDA’s review timeline once a company submits a new drug application (NDA). It does not skip any clinical trial steps. Each therapy still needs to present full evidence meeting the FDA’s standards for safety and efficacy.
Compass Pathways CEO Kabir Nath was direct about this: “While the CNPV may provide process efficiencies and accelerated review timelines, an NDA submission must still meet FDA’s established standards of clinical evidence, scientific rigour, and regulatory compliance,” he told Fierce Biotech.
Some observers have raised concerns about the voucher program itself. Holly Fernandez Lynch, associate professor of medical ethics and law at the University of Pennsylvania, told BioSpace: “It’s a pretty egregious step for the White House to direct FDA with regard to specific products.” She added: “How terrible would it be for products that are really good to have a hanging cloud over them that maybe it was just politics that supported their approval.”
At Nushama, we believe safety and evidence should guide any treatment, regardless of how quickly it moves through a regulatory process.
What this could mean for people seeking treatment
If even one of these drugs receives FDA approval, it would be the first time a substance classified as a traditional psychedelic is authorized for psychiatric use. That’s a real shift for people who have not found relief through existing options.
Here is what each therapy targets:
- Psilocybin for depression (COMP360 and PSIL201): Both involve supervised sessions where a person takes a dose of synthetic psilocybin in a clinical setting, with psychological support before, during, and after. If approved, these could reach the roughly 2.8 million adults in the U.S. living with treatment-resistant depression.
- Methylone for PTSD (TSND-201): Unlike classical psychedelics, methylone does not produce hallucinations through the 5-HT2A receptor. Transcend describes it as a “neuroplastogen,” a compound that may help the brain reorganize its neural connections. For the more than 13 million Americans affected by PTSD each year, a new approved treatment would be the first in over 25 years.
These are encouraging findings. But “fast-tracked” does not mean “available tomorrow.” Even with accelerated review, Compass Pathways, the company closest to market, has indicated a potential commercial launch by late 2026 or 2027. The others could follow on a similar or longer timeline.
Where ketamine therapy fits right now
While these new psychedelic therapies move through the approval process, ketamine-assisted therapy is the most studied and widely available psychedelic-adjacent treatment for mental health conditions today.
A few important distinctions:
Ketamine is available now. IV ketamine (intravenous ketamine, delivered directly into the bloodstream) has been used in clinical settings for decades. It is FDA-approved as an anesthetic, and its use for depression, PTSD, anxiety, and other conditions is off-label but supported by a growing body of clinical evidence. Esketamine (Spravato), a nasal spray derived from one of ketamine’s two molecular components, received FDA approval for treatment-resistant depression in 2019 and generated over $1.6 billion in sales in 2025, according to Genetic Engineering & Biotechnology News.
Ketamine works through a different brain pathway. Psilocybin acts primarily on serotonin (5-HT2A) receptors. Ketamine targets the glutamate system through NMDA receptor antagonism, a mechanism that may promote neuroplasticity (the brain’s ability to form and reorganize neural connections). This distinction matters practically: people taking SSRIs or SNRIs can generally continue their current medications during ketamine treatment without the risk of serotonin syndrome, a dangerous interaction that would require tapering off antidepressants before starting psilocybin therapy.
IV delivery allows precise, real-time clinical control. When ketamine is delivered intravenously, a physician can adjust the dose in real time based on how each person responds. At Nushama, our medical team monitors every session and titrates the infusion individually. This precision is a core reason we center our practice around IV ketamine rather than at-home or intranasal options, which tend to be less predictable in their absorption and effects.
The evidence for ketamine and PTSD keeps growing. A 2025 study published in the Journal of Psychopharmacology by MacConnel, Earleywine, and Radowitz, “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm,” examined 117 people with treatment-resistant PTSD who received IV ketamine in a therapeutic setting emphasizing preparation, integration, and sensory immersion. Of those, 75% showed a clinically significant reduction in symptoms, and 62% reached remission. A separate randomized controlled trial from the Icahn School of Medicine at Mount Sinai found that repeated IV ketamine infusions over two weeks significantly reduced chronic PTSD symptoms.
None of this means ketamine is “better” than psilocybin or methylone. These are different tools with different mechanisms, and the evidence for each is at a different stage. What it does mean: ketamine therapy is here, it has a strong evidence base, and for many people, it does not require waiting for a future FDA decision.
Why safety standards matter more than speed
We welcome the FDA’s interest in expanding access to mental health treatments. More tools, in the hands of well-trained clinicians, can mean more people find relief.
But how these tools reach people matters just as much. The executive order has drawn valid criticism for the role of political influence in drug approval. At the same time, each of the three voucher recipients has completed or is completing large-scale clinical trials. The science behind these therapies is real.
Whatever the therapy, whether ketamine, psilocybin, or methylone, effective psychedelic-assisted care includes:
- Thorough medical screening to identify contraindications
- Medically supervised dosing with real-time monitoring
- Preparation and integration support before and after each session
- A safe, calming environment designed to support the experience
These aren’t optional additions. They are the foundation. At Nushama, preparation and integration are built into every treatment plan because the medicine itself is a catalyst for change. The lasting benefits come from the work you do around it.
What you can do right now
If you have been watching these developments and wondering whether psychedelic-assisted therapy could help, here is our honest guidance:
If you are living with treatment-resistant depression, PTSD, anxiety, or another condition that has not responded to standard treatments, you do not need to wait for psilocybin or methylone to become available. IV ketamine therapy is accessible today, supported by clinical evidence, and delivered under direct medical supervision.
If you are a caregiver or family member researching options for someone you love, we are glad to walk you through what the evidence supports and what treatment involves. A consultation with our care team is a good place to start.
If you are a clinician or referring provider, these FDA actions will likely prompt questions from people in your care. We are happy to discuss how ketamine-assisted therapy fits into a broader treatment plan.
The mental health crisis in this country is not waiting for regulatory timelines. If you are ready to explore your options, speak with our care team to learn whether ketamine-assisted therapy may be a fit for you.
FAQs
What psychedelic drugs did the FDA fast-track?
- The FDA issued priority review vouchers for two psilocybin-based therapies (one for treatment-resistant depression, one for major depressive disorder) and one methylone-based therapy for PTSD. The recipients are Compass Pathways, Usona Institute, and Transcend Therapeutics (being acquired by Otsuka Pharmaceutical).
Does this mean psilocybin or methylone is now FDA-approved?
- No. A priority voucher speeds up the FDA’s review process once a company submits its application, but it does not guarantee approval. Each drug still needs to meet the FDA’s full standards for safety and efficacy. The first approval could potentially come by late 2026 or 2027.
How is ketamine different from psilocybin?
- Ketamine and psilocybin work through different brain pathways. Ketamine targets the glutamate system via NMDA receptor antagonism, while psilocybin acts on serotonin (5-HT2A) receptors. People on SSRIs or other serotonin-based medications can generally continue those medications during ketamine treatment, while psilocybin therapy would typically require tapering off first. Ketamine sessions also tend to be shorter (roughly 40 to 60 minutes for an IV infusion) compared to psilocybin sessions, which can last several hours.
Is ketamine therapy available right now?
- Yes. IV ketamine has been used in clinical settings for decades and is available today for conditions including treatment-resistant depression, PTSD, anxiety, and more. Esketamine (Spravato), a related nasal spray, has been FDA-approved for treatment-resistant depression since 2019.
What should I do if I’m interested in psychedelic-assisted therapy?
- If you are living with a condition that has not responded to conventional treatments, you can explore ketamine-assisted therapy now rather than waiting for psilocybin or methylone to reach the market. A good first step is to book a consultation with a care team that can review your history, discuss your goals, and help determine if this approach may support your path forward.